Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. The scenarios in ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday ...